James C. Lin
Lawyers
Filters
CANbridge Pharmaceuticals HK$685 million IPO
We advised CANbridge Pharmaceuticals on its IPO and HKEX listing
FiscalNote business combination with Duddell Street Acquisition Corp.
We are advising Duddell Street, a SPAC, on the transaction
Sea $6.9 billion concurrent convertible notes and equity offerings
We advised the joint book-running managers on the concurrent offerings of convertible senior notes and ADSs
Baidu $1 billion notes offering
We advised the underwriters on the investment-grade debt offering
Baidu $1 billion sustainability notes offering
The investment-grade offering included notes due 2027 and 2031
SOPHiA GENETICS $234 million IPO and $20 million private placement
We advised SOPHiA GENETICS on its IPO, Nasdaq listing and concurrent private placement
Black Spade Acquisition $150 million IPO
We advised Black Spade, a SPAC, on its IPO and NYSE listing
Gobi Acquisition $250 million IPO
We advised the joint book-running managers on the SPAC IPO and Nasdaq listing
Magnum Opus Acquisition $200 million IPO
We advised the underwriters on the SPAC IPO and NYSE listing
HUTCHMED HK$4.17 billion IPO and primary listing
The shares are listed on the Hong Kong Stock Exchange